Diagnosis of invasive pulmonary aspergillosis: Updates and recommendations

Medecine et Maladies Infectieuses

Volumn 44, Issue 3, 2014, Pages 89-101

  Desoubeaux, G ^a,b   Bailly, E ^a   Chandenier, J ^a,b  

^a UNIVERSITY HOSPITAL OF TOURS   (France)

^b UNIVERSITÉ DE TOURS   (France)

Author keywords

Invasive aspergillosis; Recommendations

Indexed keywords

BETA DEXTRO GLUCAN; GALACTOMANNAN; GLUCAN; UNCLASSIFIED DRUG; BETA GLUCAN; BIOLOGICAL MARKER; FUNGAL DNA; FUNGUS ANTIBODY; FUNGUS ANTIGEN; MANNAN;

ANTIGEN DETECTION; DIAGNOSTIC IMAGING; EARLY DIAGNOSIS; FUNGUS CULTURE; HISTOPATHOLOGY; HUMAN; INVASIVE ASPERGILLOSIS; LUNG ASPERGILLOSIS; MOLECULAR DIAGNOSIS; PATHOPHYSIOLOGY; POPULATION RISK; PREDICTIVE VALUE; REAL TIME POLYMERASE CHAIN REACTION; REVIEW; SYMPTOM ASSESSMENT; ASPERGILLUS; BIOPSY; BLOOD; COMPUTER ASSISTED TOMOGRAPHY; EUROPE; GROWTH, DEVELOPMENT AND AGING; IMMUNOCOMPROMISED PATIENT; IMMUNOLOGY; INVASIVE PULMONARY ASPERGILLOSIS; ISOLATION AND PURIFICATION; PATHOLOGY; PRACTICE GUIDELINE; SENSITIVITY AND SPECIFICITY;

ANTIBODIES, FUNGAL; ANTIGENS, FUNGAL; ASPERGILLUS; BETA-GLUCANS; BIOLOGICAL MARKERS; BIOPSY; DIAGNOSTIC IMAGING; DNA, FUNGAL; EARLY DIAGNOSIS; EUROPE; HUMANS; IMMUNOCOMPROMISED HOST; INVASIVE PULMONARY ASPERGILLOSIS; MANNANS; PRACTICE GUIDELINES AS TOPIC; PREDICTIVE VALUE OF TESTS; REAL-TIME POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84896491459     PISSN: 0399077X     EISSN: 17696690     Source Type: Journal    
DOI: 10.1016/j.medmal.2013.11.006     Document Type: Review

References (63)

1. Denning D.W. Invasive aspergillosis. Clin Infect Dis 1998, 26(4):781-803. [quiz 804-5].
2. Kousha M., Tadi R., Soubani A.O. Pulmonary aspergillosis: a clinical review. Eur Respir Rev 2011, 20(121):156-174.
3. Lortholary O., Gangneux J.P., Sitbon K., Lebeau B., de Monbrison F., Le Strat Y., et al. Epidemiological trends in invasive aspergillosis in France: the SAIF network (2005-2007). Clin Microbiol Infect 2011, 17(12):1882-1889.
4. Freifeld A.G., Bow E.J., Sepkowitz K.A., Boeckh M.J., Ito J.I., Mullen C.A., et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 2011, 52(4):e56-e93.
5. Salman N., Törün S.H., Budan B., Somer A. Invasive aspergillosis in hematopoietic stem cell and solid organ transplantation. Expert Rev Anti Infect Ther 2011, 9(3):307-315.
6. Gangneux J.P., Camus C., Philippe B. Epidemiology of invasive aspergillosis and risk factors in non neutropaenic patients. Rev Mal Respir 2010, 27(8):e34-e46.
7. Dimopoulos G., Frantzeskaki F., Poulakou G., Armaganidis A. Invasive aspergillosis in the intensive care unit. Ann N Y Acad Sci 2012, 1272:31-39.
8. Herbrecht R., Denning D.W., Patterson T.F., Bennett J.E., Greene R.E., Oestmann J.W., et al. Voriconazole versus amphotericinB for primary therapy of invasive aspergillosis. N Engl J Med 2002, 347(6):408-415.
9. Kontoyiannis D.P., Marr K.A., Park B.J., Alexander B.D., Anaissie E.J., Walsh T.J., et al. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) database. Clin Infect Dis 2010, 50(8):1091-1100.
10. De Pauw B.E., Viscoli C. Managing invasive fungal infections: relying on clinical instincts or on a rational navigation system?. J Antimicrob Chemother 2011, 66(Suppl.1):i55-i58.
11. De Pauw B., Walsh T.J., Donnelly J.P., Stevens D.A., Edwards J.E., Calandra T., et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008, 46(12):1813-1821.
12. Marchetti O., Lamoth F., Mikulska M., Viscoli C., Verweij P., Bretagne S. ECIL recommendations for the use of biological markers for the diagnosis of invasive fungal diseases in leukemic patients and hematopoietic SCT recipients. Bone Marrow Transplant [Internet] 2011, [cité 28 sept 2011]. http://www.ncbi.nlm.nih.gov/pubmed/21927034.
13. Arendrup M.C., Bille J., Dannaoui E., Ruhnke M., Heussel C.P., Kibbler C. ECIL-3 classical diagnostic procedures for the diagnosis of invasive fungal diseases in patients with leukaemia. Bone Marrow Transplant 2012, 47(8):1030-1045.
14. Desoubeaux G. Connaissances actuelles sur la maladie aspergillaire 2011, Éditions universitaires européennes, Sarrebruck, Germany.
15. Bergeron A., Porcher R., Sulahian A., de Bazelaire C., Chagnon K., Raffoux E., et al. The strategy for the diagnosis of invasive pulmonary aspergillosis should depend on both the underlying condition and the leukocyte count of patients with hematologic malignancies. Blood 2012, 119(8):1831-1837. [quiz 1956].
16. Neofytos D., Horn D., Anaissie E., Steinbach W., Olyaei A., Fishman J., et al. Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry. Clin Infect Dis 2009, 48(3):265-273.
17. Marr K.A., Carter R.A., Boeckh M., Martin P., Corey L. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood 2002, 100(13):4358-4366.
18. Marr K.A., Carter R.A., Crippa F., Wald A., Corey L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002, 34(7):909-917.
19. Post M.J., Lass-Floerl C., Gastl G., Nachbaur D. Invasive fungal infections in allogeneic and autologous stem cell transplant recipients: a single-center study of 166 transplanted patients. Transpl Infect Dis 2007, 9(3):189-195.
20. De Rosa F.G., Shaz D., Campagna A.C., Dellaripa P.E., Khettry U., Craven D.E. Invasive pulmonary aspergillosis soon after therapy with infliximab, a tumor necrosis factor-alpha-neutralizing antibody: a possible healthcare-associated case?. Infect Control Hosp Epidemiol 2003, 24(7):477-482.
21. Stevens D.A., Melikian G.L. Aspergillosis in the nonimmunocompromised host. Immunol Invest 2011, 40(7-8):751-766.
22. Caillot D., Casasnovas O., Bernard A., Couaillier J.F., Durand C., Cuisenier B., et al. Improved management of invasive pulmonary aspergillosis in neutropenic patients using early thoracic computed tomographic scan and surgery. J Clin Oncol 1997, 15(1):139-147.
23. Caillot D., Mannone L., Cuisenier B., Couaillier J.F. Role of early diagnosis and aggressive surgery in the management of invasive pulmonary aspergillosis in neutropenic patients. Clin Microbiol Infect 2001, 7(Suppl.2):54-61.
24. Hope W.W., Walsh T.J., Denning D.W. Laboratory diagnosis of invasive aspergillosis. Lancet Infect Dis 2005, 5(10):609-622.
25. Marr K.A., Leisenring W. Design issues in studies evaluating diagnostic tests for aspergillosis. Clin Infect Dis 2005, 41(Suppl.6):S381-S386.
26. Slobbe L., Polinder S., Doorduijn J.K., Lugtenburg P.J., el Barzouhi A., Steyerberg E.W., et al. Outcome and medical costs of patients with invasive aspergillosis and acute myelogenous leukemia-myelodysplastic syndrome treated with intensive chemotherapy: an observational study. Clin Infect Dis 2008, 47(12):1507-1512.
27. Meersseman W., Vandecasteele S.J., Wilmer A., Verbeken E., Peetermans W.E., Van Wijngaerden E. Invasive aspergillosis in critically ill patients without malignancy. Am J Respir Crit Care Med 2004, 170(6):621-625.
28. Caillot D., Latrabe V., Thiébaut A., Herbrecht R., De Botton S., Pigneux A., et al. Computer tomography in pulmonary invasive aspergillosis in hematological patients with neutropenia: a useful tool for diagnosis and assessment of outcome in clinical trials. Eur J Radiol 2010, 74(3):e172-e175.
29. Greene R.E., Schlamm H.T., Oestmann J.W., Stark P., Durand C., Lortholary O., et al. Imaging findings in acute invasive pulmonary aspergillosis: clinical significance of the halo sign. Clin Infect Dis 2007, 44(3):373-379.
30. Caillot D., Couaillier J.F., Bernard A., Casasnovas O., Denning D.W., Mannone L., et al. Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computed tomography scans in patients with neutropenia. J Clin Oncol 2001, 19(1):253-259.
31. Georgiadou S.P., Sipsas N.V., Marom E.M., Kontoyiannis D.P. The diagnostic value of halo and reversed halo signs for invasive mold infections in compromised hosts. Clin Infect Dis 2011, 52(9):1144-1155.
32. Francesconi A., Kasai M., Petraitiene R., Petraitis V., Kelaher A.M., Schaufele R., et al. Characterization and comparison of galactomannan enzyme immunoassay and quantitative real-time PCR assay for detection of Aspergillus fumigatus in bronchoalveolar lavage fluid from experimental invasive pulmonary aspergillosis. J Clin Microbiol 2006, 44(7):2475-2480.
33. Balajee S.A., Houbraken J., Verweij P.E., Hong S.B., Yaghuchi T., Varga J., et al. Aspergillus species identification in the clinical setting. Stud Mycol 2007, 59:39-46.
34. De Carolis E., Posteraro B., Lass-Flörl C., Vella A., Florio A.R., Torelli R., et al. Species identification of Aspergillus, Fusarium and Mucorales with direct surface analysis by matrix-assisted laser desorption ionization time-of-flight mass spectrometry. Clin Microbiol Infect 2012, 18(5):475-484.
35. Horvath J.A., Dummer S. The use of respiratory-tract cultures in the diagnosis of invasive pulmonary aspergillosis. Am J Med 1996, 100(2):171-178.
36. Bardana E.J., Gerber J.D., Craig S., Cianciulli F.D. The general and specific humoral immune response to pulmonary aspergillosis. Am Rev Respir Dis 1975, 112(6):799-805.
37. Bardalaye P.C., Nordin J.H. Chemical structure of the galactomannan from the cell wall of Aspergillus niger. J Biol Chem 1977, 252(8):2584-2591.
38. Wheat L.J. Rapid diagnosis of invasive aspergillosis by antigen detection. Transpl Infect Dis 2003, 5(4):158-166.
39. Maertens J.A., Klont R., Masson C., Theunissen K., Meersseman W., Lagrou K., et al. Optimization of the cutoff value for the Aspergillus double-sandwich enzyme immunoassay. Clin Infect Dis 2007, 44(10):1329-1336.
40. Maertens J., Theunissen K., Verbeken E., Lagrou K., Verhaegen J., Boogaerts M., et al. Prospective clinical evaluation of lower cut-offs for galactomannan detection in adult neutropenic cancer patients and haematological stem cell transplant recipients. Br J Haematol 2004, 126(6):852-860.
41. Bergeron A., Porcher R., Menotti J., Poirot J.L., Chagnon K., Vekhoff A., et al. Prospective evaluation of clinical and biological markers to predict the outcome of invasive pulmonary aspergillosis in hematological patients. J Clin Microbiol 2012, 50(3):823-830.
42. Boutboul F., Alberti C., Leblanc T., Sulahian A., Gluckman E., Derouin F., et al. Invasive aspergillosis in allogeneic stem cell transplant recipients: increasing antigenemia is associated with progressive disease. Clin Infect Dis 2002, 34(7):939-943.
43. Leeflang M.M., Debets-Ossenkopp Y.J., Visser C.E., Scholten R.J.P.M., Hooft L., Bijlmer H.A., et al. Galactomannan detection for invasive aspergillosis in immunocompromized patients. Cochrane Database Syst Rev 2008, 4:CD007394.
44. Wheat L.J., Walsh T.J. Diagnosis of invasive aspergillosis by galactomannan antigenemia detection using an enzyme immunoassay. Eur J Clin Microbiol Infect Dis 2008, 27(4):245-251.
45. Pfeiffer C.D., Fine J.P., Safdar N. Diagnosis of invasive aspergillosis using a galactomannan assay: a meta-analysis. Clin Infect Dis 2006, 42(10):1417-1427.
46. Marr K.A., Laverdiere M., Gugel A., Leisenring W. Antifungal therapy decreases sensitivity of the Aspergillus galactomannan enzyme immunoassay. Clin Infect Dis 2005, 40(12):1762-1769.
47. Klont R.R., Mennink-Kersten M.A.S.H., Verweij P.E. Utility of Aspergillus antigen detection in specimens other than serum specimens. Clin Infect Dis 2004, 39(10):1467-1474.
48. Guo Y.-L., Chen Y.Q., Wang K., Qin S.M., Wu C., Kong J.L. Accuracy of BAL galactomannan in diagnosing invasive aspergillosis: a bivariate metaanalysis and systematic review. Chest 2010, 138(4):817-824.
49. Meersseman W., Lagrou K., Maertens J., Wilmer A., Hermans G., Vanderschueren S., et al. Galactomannan in bronchoalveolar lavage fluid a tool for diagnosing aspergillosis in intensive care unit patients. Am J Respir Crit Care Med 2008, 177(1):27-34.
50. Obayashi T., Yoshida M., Mori T., Goto H., Yasuoka A., Iwasaki H., et al. Plasma (1→3)-beta-D-glucan measurement in diagnosis of invasive deep mycosis and fungal febrile episodes. Lancet 1995, 345(8941):17-20.
51. Odabasi Z., Mattiuzzi G., Estey E., Kantarjian H., Saeki F., Ridge R.J., et al. Beta-D-glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome. Clin Infect Dis 2004, 39(2):199-205.
52. Karageorgopoulos D.E., Vouloumanou E.K., Ntziora F., Michalopoulos A., Rafailidis P.I., Falagas M.E. β-D-glucan assay for the diagnosis of invasive fungal infections: a meta-analysis. Clin Infect Dis 2011, 52(6):750-770.
53. Pazos C., Pontón J., Del Palacio A. Contribution of (1→3)-beta-D-glucan chromogenic assay to diagnosis and therapeutic monitoring of invasive aspergillosis in neutropenic adult patients: a comparison with serial screening for circulating galactomannan. J Clin Microbiol 2005, 43(1):299-305.
54. Koo S., Baden L.R., Marty F.M. Post-diagnostic kinetics of the (1→3)-β-D-glucan assay in invasive aspergillosis, invasive candidiasis and Pneumocystis jirovecii pneumonia. Clin Microbiol Infect 2012, 18(5):E122-E127.
55. White P.L., Bretagne S., Klingspor L., Melchers W.J.G., McCulloch E., Schulz B., et al. Aspergillus PCR: one step closer to standardization. J Clin Microbiol 2010, 48(4):1231-1240.
56. Tuon F.F. A systematic literature review on the diagnosis of invasive aspergillosis using polymerase chain reaction (PCR) from bronchoalveolar lavage clinical samples. Rev Iberoam Micol 2007, 24(2):89-94.
57. Mengoli C., Cruciani M., Barnes R.A., Loeffler J., Donnelly J.P. Use of PCR for diagnosis of invasive aspergillosis: systematic review and meta-analysis. Lancet Infect Dis 2009, 9(2):89-96.
58. Suarez F., Lortholary O., Buland S., Rubio M.T., Ghez D., Mahé V., et al. Detection of circulating Aspergillus fumigatus DNA by real-time PCR assay of large serum volumes improves early diagnosis of invasive aspergillosis in high-risk adult patients under hematologic surveillance. J Clin Microbiol 2008, 46(11):3772-3777.
59. Millon L., Piarroux R., Deconinck E., Bulabois C.E., Grenouillet F., Rohrlich P., et al. Use of real-time PCR to process the first galactomannan-positive serum sample in diagnosing invasive aspergillosis. J Clin Microbiol 2005, 43(10):5097-5101.
60. Wingard J.R., Hiemenz J.W., Jantz M.A. How I manage pulmonary nodular lesions and nodular infiltrates in patients with hematologic malignancies or undergoing hematopoietic cell transplantation. Blood 2012, 120(9):1791-1800.
61. Kim J.Y., Yoo J.W., Oh M., Park S.H., Shim T.S., Choi Y.Y., et al. (18)F-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography findings are different between invasive and noninvasive pulmonary aspergillosis. J Comput Assist Tomogr 2013, 37(4):596-601.
62. Baxter C.G., Bishop P., Low S.E., Baiden-Amissah K., Denning D.W. Pulmonary aspergillosis: an alternative diagnosis to lung cancer after positive [18F]FDG positron emission tomography. Thorax 2011, 66(7):638-640.
63. Maertens J.A., Nucci M., Donnelly J.P. The role of antifungal treatment in hematology. Haematologica 2012, 97(3):325-327.